Back to Search
Start Over
Everestmab, a novel long-acting GLP-1/anti GLP-1R nanobody fusion protein, exerts potent anti-diabetic effects
- Source :
- Artificial Cells, Nanomedicine, and Biotechnology. 48:854-866
- Publication Year :
- 2020
- Publisher :
- Informa UK Limited, 2020.
-
Abstract
- In the present study, a novel single domain antibody (sdAb) fusion protein, named everestmab, composing of a mutated GLP-1(A8G) fused to the tandem bispecific humanized GLP-1R-targeting and albumin-binding nanobodies was designed and characterized for the therapies for type 2 diabetes mellitus (T2DM). Surface plasmon resonance (SPR) measurements demonstrated everestmab associates with serum albumins of rat and monkey species with high affinity, and tends to be cross-reactive with rat and monkey species.
- Subjects :
- Male
endocrine system
Recombinant Fusion Proteins
Biomedical Engineering
Pharmaceutical Science
Medicine (miscellaneous)
02 engineering and technology
Carbohydrate metabolism
Pharmacology
Glucagon-Like Peptide-1 Receptor
Rats, Sprague-Dawley
03 medical and health sciences
0302 clinical medicine
Glucagon-Like Peptide 1
medicine
Animals
Hypoglycemic Agents
Tissue Distribution
Chemistry
digestive, oral, and skin physiology
Albumin
General Medicine
Single-Domain Antibodies
021001 nanoscience & nanotechnology
Human serum albumin
Fusion protein
Rats
Macaca fascicularis
Long acting
Single-domain antibody
Diabetes Mellitus, Type 2
030220 oncology & carcinogenesis
0210 nano-technology
hormones, hormone substitutes, and hormone antagonists
Biotechnology
medicine.drug
Subjects
Details
- ISSN :
- 2169141X and 21691401
- Volume :
- 48
- Database :
- OpenAIRE
- Journal :
- Artificial Cells, Nanomedicine, and Biotechnology
- Accession number :
- edsair.doi.dedup.....4cf64555eca0f00cbd21e62b118ee223